Literature DB >> 16814428

Selective loss of synaptic proteins in Alzheimer's disease: evidence for an increased severity with APOE varepsilon4.

Rudi K Tannenberg1, Heather L Scott, Anthony E G Tannenberg, Peter R Dodd.   

Abstract

A pathological feature of Alzheimer's disease (AD) is an area-specific neuronal loss that may be caused by excitotoxicity-related synaptic dysfunction. Relative expression levels of synaptophysin, dynamin I, complexins I and II, N-cadherin, and alphaCaMKII were analysed in human brain tissue from AD cases and controls in hippocampus, and inferior temporal and occipital cortices. Synaptophysin and dynamin I are presynaptic terminal proteins not specific to any neurotransmitter system whereas complexin II, N-cadherin, and alphaCaMKII are specific for excitatory synapses. Complexin I is a presynaptic protein localised to inhibitory synapses. There were no significant differences in synaptophysin, dynamin I, N-cadherin, or alphaCaMKII protein levels between AD cases and controls. The complexin proteins were both markedly lower in AD cases than in controls (P < 0.01). Cases were also categorised by APOE genotype. Averaged across areas there was a 36% lowering of presynaptic proteins in AD cases carrying at least one epsilon4 allele compared with in AD cases lacking the epsilon4 allele. We infer that synaptic protein level is not indicative of neuronal loss, but the synaptic dysfunction may result from the marked relative loss of the complexins in AD, and lower levels of presynaptic proteins in AD cases with the APOE epsilon4 allele.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16814428     DOI: 10.1016/j.neuint.2006.05.004

Source DB:  PubMed          Journal:  Neurochem Int        ISSN: 0197-0186            Impact factor:   3.921


  34 in total

Review 1.  Synaptic Vesicle-Recycling Machinery Components as Potential Therapeutic Targets.

Authors:  Ying C Li; Ege T Kavalali
Journal:  Pharmacol Rev       Date:  2017-04       Impact factor: 25.468

2.  Dysregulated phosphorylation of Ca(2+) /calmodulin-dependent protein kinase II-α in the hippocampus of subjects with mild cognitive impairment and Alzheimer's disease.

Authors:  Lindsay C Reese; Fernanda Laezza; Randall Woltjer; Giulio Taglialatela
Journal:  J Neurochem       Date:  2011-09-28       Impact factor: 5.372

Review 3.  Cerebrospinal Fluid Biomarkers of Alzheimer's Disease: Current Evidence and Future Perspectives.

Authors:  Donovan A McGrowder; Fabian Miller; Kurt Vaz; Chukwuemeka Nwokocha; Cameil Wilson-Clarke; Melisa Anderson-Cross; Jabari Brown; Lennox Anderson-Jackson; Lowen Williams; Lyndon Latore; Rory Thompson; Ruby Alexander-Lindo
Journal:  Brain Sci       Date:  2021-02-10

Review 4.  Is synaptic loss a unique hallmark of Alzheimer's disease?

Authors:  Stephen W Scheff; Janna H Neltner; Peter T Nelson
Journal:  Biochem Pharmacol       Date:  2014-01-09       Impact factor: 5.858

Review 5.  The role of synaptic microRNAs in Alzheimer's disease.

Authors:  Subodh Kumar; P Hemachandra Reddy
Journal:  Biochim Biophys Acta Mol Basis Dis       Date:  2020-08-20       Impact factor: 5.187

6.  Dynamics of subcellular proteomes during brain development.

Authors:  Daniel B McClatchy; Lujian Liao; Ji Hyoung Lee; Sung Kyu Park; John R Yates
Journal:  J Proteome Res       Date:  2012-03-26       Impact factor: 4.466

7.  Cognitive enhancing treatment with a PPARγ agonist normalizes dentate granule cell presynaptic function in Tg2576 APP mice.

Authors:  Miroslav N Nenov; Fernanda Laezza; Sigmund J Haidacher; Yingxin Zhao; Rovshan G Sadygov; Jonathan M Starkey; Heidi Spratt; Bruce A Luxon; Kelly T Dineley; Larry Denner
Journal:  J Neurosci       Date:  2014-01-15       Impact factor: 6.167

8.  Apolipoprotein E highly correlates with AbetaPP- and tau-related markers in human cerebrospinal fluid.

Authors:  Simona Vuletic; Ge Li; Elaine R Peskind; Hal Kennedy; Santica M Marcovina; James B Leverenz; Eric C Petrie; Virginia M-Y Lee; Douglas Galasko; Gerard D Schellenberg; John J Albers
Journal:  J Alzheimers Dis       Date:  2008-11       Impact factor: 4.472

9.  Increased complexin-1 and decreased miR-185 expression levels in Behçet's disease with and without neurological involvement.

Authors:  Elif Uğurel; Elçin Şehitoğlu; Erdem Tüzün; Murat Kürtüncü; Arzu Çoban; Burçak Vural
Journal:  Neurol Sci       Date:  2015-11-14       Impact factor: 3.307

10.  Meta-analysis of synaptic pathology in Alzheimer's disease reveals selective molecular vesicular machinery vulnerability.

Authors:  Martijn C de Wilde; Cassia R Overk; John W Sijben; Eliezer Masliah
Journal:  Alzheimers Dement       Date:  2016-01-14       Impact factor: 21.566

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.